MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia

Leukemia

Volumn 27, Issue 8, 2013, Pages 1722-1728

  Jimenez C ^a   Sebastian E ^a   Chillon M C ^a,b   Giraldo, P ^c   Mariano Hernandez J ^d   Escalante, F ^e   Gonzalez Lopez T J ^f   Aguilera, C ^g   De Coca, A G ^h   Murillo, I ^c   Alcoceba, M ^a   Balanzategui, A ^a   Sarasquete, M E ^a,b   Corral, R ^a   Marin L A ^a   Paiva, B ^a,b   Ocio, E M ^a,b   Gutierrez N C ^a,b   Gonzalez M ^a,b   San Miguel, J F ^a,b   Garcia Sanz R ^a,b   more..

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b Centro de Investigacion del Cancer   (Spain)

^c HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^d HOSPITAL GENERAL DE SEGOVIA   (Spain)

^e Hospital Virgen Blanca   (Spain)

^f HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^g HOSPITAL EL BIERZO   (Spain)

^h HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

Author keywords

diagnosis; IgM monoclonal gammapathies; immunophenotyping; MYD88 mutations; prognosis; Waldenstr m's macroglobulinemia

Indexed keywords

CD23 ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN M; LACTATE DEHYDROGENASE; MYELOID DIFFERENTIATION FACTOR 88;

AMYLOIDOSIS; ARTICLE; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; FOLLOW UP; GENE MUTATION; HAIRY CELL LEUKEMIA; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHOCYTOSIS; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MINIMAL RESIDUAL DISEASE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NEUROPATHY; PRIORITY JOURNAL; SOMATIC HYPERMUTATION; SOMATIC MUTATION; SPLENIC MARGINAL ZONE LYMPHOMA; WALDENSTROEM MACROGLOBULINEMIA;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; IMMUNOGLOBULIN M; LYMPHOPROLIFERATIVE DISORDERS; MIDDLE AGED; MUTATION; MYELOID DIFFERENTIATION FACTOR 88; NEOPLASM, RESIDUAL; WALDENSTROM MACROGLOBULINEMIA;

EID: 84881482021     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.62     Document Type: Article

References (44)

1. Groves FD, Travis LB, Devesa SS, Ries LA, Fraumeni Jr JF. Waldenstrom's macro-globulinemia: incidence patterns in the United States, 1988-1994. Cancer 1998; 82: 1078-1081. (Pubitemid 28136520)
2. Herrinton LJ, Weiss NS. Incidence of Waldenstrom's macroglobulinemia. Blood 1993; 82: 3148-3150. (Pubitemid 23334943)
3. Garcia-Sanz R, Montoto S, Torrequebrada A, de Coca AG, Petit J, Sureda A et al. Waldenstrom macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol 2001; 115: 575-582. (Pubitemid 34019184)
4. Phekoo KJ, Jack RH, Davies E, M1ller H, Schey SA. The incidence and survival of Waldenstrom's macroglobulinaemia in South East England. Leukemia Res 2008; 32: 55-59. (Pubitemid 350103805)
5. Braggio E, Philipsborn C, Novak A, Hodge L, Ansell S, Fonseca R. Molecular pathogenesis of Waldenström macroglobulinemia. Haematologica 2012; 97: 1281-1290.
6. Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J M 2012; 367: 826-833.
7. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011; 470: 115-119.
8. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci 2012; 109: 3879-3884.
9. Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011; 43: 830-837.
10. Pham-Ledard A, Cappellen D, Martinez F, Vergier B, Beylot-Barry M, Merlio JP. myd88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, Leg type. J Invest Dermatol 2012; 132: 2118-2120.
11. Gonzalez-Aguilar A, Idbaih A, Boisselier B, Habbita N, Rossetto M, Laurenge A et al. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res 2012; 18: 5203-5211.
12. Montesinos-Rongen M, Godlewska E, Brunn A, Wiestler OD, Siebert R, Deckert M. Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma. Acta Neuropathol 2011; 122: 791-792.
13. Ocio EM, Del CD, Caballero A, Alonso J, Paiva B, Pesoa R et al. Differential diagnosis of IgM MGUS and WM according to B-lymphoid infiltration by morphology and flow cytometry. Clin Lymphoma Myeloma Leuk 2011; 11: 93-95.
14. Billadeau D, Quam L, Thomas W, Kay N, Greipp P, Kyle R et al. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood 1992; 80: 1818-1824.
15. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011; 117: 5019-5032.
16. Owen RG, Treon SP, Al Katib A, Fonseca R, Greipp PR, McMaster ML et al. Clin-icopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30: 110-115. (Pubitemid 36506291)
17. Paiva B, Vidriales MB, Perez JJ, Mateo G, Montalban MA, Mateos MV et al. Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. Haematologica 2009; 94: 1599-1602.
18. Garcia-Sanz R, Ocio E, Caballero A, Magalhaes RJ, Alonso J, Lopez-Anglada L et al. Post-treatment bone marrow residual disease45% by flow cytometry is highly predictive of short progression-free and overall survival in patients with Wal-denstrom's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011; 11: 168-171.
19. Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008; 93: 431-438. (Pubitemid 351398645)
20. van Dongen JJ, Lhermitte L, Bottcher S, Almeida J, van dV V, Flores-Montero J et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012; 26: 1908-1975.
21. Pedreira CE, Costa ES, Almeida J, Fernandez C, Quijano S, Flores J et al. A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B-cell chronic lymphoproliferative disorders. Cytometry A 2008; 73A: 1141-1150.
22. Ocio EM, Schop RF, Gonzalez B, Van Wier SA, Hernandez-Rivas JM, Gutierrez NC et al. 6q deletion in Waldenstrom macroglobulinemia is associated with features of adverse prognosis. Br J Haematol 2007; 136: 80-86. (Pubitemid 44912591)
23. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257-2317. (Pubitemid 38072572)
24. Martin-Jimenez P, Garcia-Sanz R, Balanzategui A, Alcoceba M, Ocio E, Sanchez ML et al. Molecular characterization of heavy chain immunoglobulin gene rearrangements in Waldenstrom's macroglobulinemia and IgM monoclonal gammo-pathy of undetermined significance. Haematologica 2007; 92: 635-642. (Pubitemid 350144265)
25. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364: 1046-1060.
26. Treon SP. How I treat Waldenstrom macroglobulinemia. Blood 2009; 114: 2375-2385.
27. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 2006; 108: 2520-2530.
28. Kyle RA, Buadi F, Rajkumar SV. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Oncology (Williston Park) 2011; 25: 578-586.
29. Gachard N, Parrens M, Soubeyran I, Petit B, Marfak A, Rizzo D et al. IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenstrom macroglobulinemia/lymphoplasmacytic lymphomas. Leukemia 2013; 27: 183-189.
30. Varettoni M, Arcaini L, Zibellini S, Boveri E, Rattotti S, Riboni R et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrm's macroglobulinemia and related lymphoid neoplasms. Blood 2013, e-pub ahead of print 25 January 2013.
31. Wang CZ, Lin J, Qian J, Shao R, Xue D, Qian W et al. Development of highresolution melting analysis for the detection of the MYD88 L265P mutation. Clin Biochem 2012; 46: 385-387.
32. Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X et al. MYD88 L265P in Walden-ström's macroglobulinemia, IgM monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific PCR. Blood 2013, e-pub ahead of print 15 January 2013.
33. Landgren O, Staudt LM. MYD88 L265P Somatic Mutation in IgM MGUS. N Engl J Med 2012; 367: 2255-2257.
34. Je EM, Yoo NJ, Lee SH. Absence of MYD88 gene mutation in acute leukemias and multiple myelomas. Eur J Haematol 2012; 88: 273-274.
35. Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475: 101-105.
36. Xu Z, Zan H, Pone EJ, Mai T, Casali P. Immunoglobulin class-switch DNA recombination: induction, targeting and beyond. Nat Rev Immunol 2012; 12: 517-531.
37. San Miguel JF, Vidriales MB, Ocio E, Mateo G, Sanchez-Guijo F, Sanchez ML et al. Immunophenotypic analysis of Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30: 187-195. (Pubitemid 36506307)
38. Ocio EM, Hernandez JM, Mateo G, Sanchez ML, Gonzalez B, Vidriales B et al. Immunophenotypic and cytogenetic comparison of Waldenstrom's macro-globulinemia with splenic marginal zone lymphoma. Clin Lymphoma 2005; 5: 241-245. (Pubitemid 40614234)
39. Sahota SS, Babbage G, Weston-Bell NJ. CD27 in defining memory B-cell origins in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2009; 9: 33-35.
40. Kriangkum J, Taylor BJ, Treon SP, Mant MJ, Belch AR, Pilarski LM. Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood. Blood 2004; 104: 2134-2142. (Pubitemid 39297868)
41. Walsh SH, Laurell A, Sundstrom G, Roos G, Sundstrom C, Rosenquist R. Lym-phoplasmacytic lymphoma/Waldenstrom's macroglobulinemia derives from an extensively hypermutated B cell that lacks ongoing somatic hypermutation. Leuk Res 2005; 29: 729-734. (Pubitemid 40779478)
42. Owen RG, Kyle RA, Stone MJ, Rawstron AC, Leblond V, Merlini G et al. Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop. Br J Haematol 2013; 160: 171-176.
43. Kimby E, Treon SP, Anagnostopoulos A, Dimopoulos M, Garcia-Sanz R, Gertz MA et al. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma 2006; 6: 380-383.
44. van der Velden V, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007; 21: 604-611. (Pubitemid 46444541)